Table Filtering
Other Information
Release Statistics Download
GlyCosmos Glycolipids

Glycolipid entries from the LIPID MAPS Structure Database (LMSD).

Source Last Updated
LIPID MAPS Proteome Database (LMSD) June 16, 2024
Displaying entries 3676 - 3700 of 6046 in total
Sub Class LM ID Name LipidBank ID KEGG ID PubChem CID ChEBI ID Exact Mass ▼ Formula
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505EL03
  • GalNAcbeta1-3Galalpha1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
  • IV 3-nLcOse4(d18:1/20:0)
44261814 1647.944742 C78H141N3O33
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506AK03
  • GalNAcbeta1-3Galalpha1-3(Galbeta1-4GlcNAcbeta1-6)Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44261894 1647.944742 C78H141N3O33
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506AM03
  • Galalpha1-3(GalNAcbeta1-4Galbeta1-4GlcNAcbeta1-6)Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44261910 1647.944742 C78H141N3O33
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BH03
  • Galbeta1-4GlcNAcbeta1-3Galalpha1-3(GalNAcbeta1-4)Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44261686 1647.944742 C78H141N3O33
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AI05
  • Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0)
  • type IV H(d18:1/24:0)
44260232 1646.985878 C80H146N2O32
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BM05
  • Fucalpha2-3Galbeta1-3GalNAcbeta1-4Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44260472 1646.985878 C80H146N2O32
GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) LMSP0503AK05
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44260568 1646.985878 C80H146N2O32
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AE05
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:0)
  • type I B antigen(d18:1/24:0)
44260648 1646.985878 C80H146N2O32
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AE05
  • Galalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:0)
  • type II B antigen(d18:1/24:0)
44261008 1646.985878 C80H146N2O32
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CV05
  • Gala 1-3Lex(d18:1/24:0)
  • Galalpha1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44261552 1646.985878 C80H146N2O32
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506AW05
  • Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44261616 1646.985878 C80H146N2O32
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BB05
  • Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44261640 1646.985878 C80H146N2O32
Gangliosides LMSP0601AN01
  • GD2(d18:1/16:0)
  • GalNAcbeta1-4(NeuAcalpha2-8NeuAcalpha2-3)Galbeta1-4Glcbeta-Cer(d18:1/16:0)
44262068 1646.887956 C76H134N4O34
Diacylglycerophosphoinositolglycans LMGP15010199
  • 2'-O-(alpha-D-Manp)-6'-O-(alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp)-(1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-1'-myo-inositol)
  • PIM5(16:0/18:1(9Z))
126457567 1646.805608 C73H131O38P
Diacylglycerophosphoinositolglycans LMGP15010208
  • 2'-O-(alpha-D-Manp)-6'-O-(alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp)-(1-octadecanoyl-2-(9Z-hexadecenoyl)-sn-glycero-3-phospho-1'-myo-inositol)
  • PIM5(18:0/16:1(9Z))
126457576 1646.805608 C73H131O38P
Diacylglycerophosphoinositolglycans LMGP15010213
  • 2'-O-(alpha-D-Manp)-6'-O-(alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp)-(1-(9Z-octadecenoyl)-2-hexadecanoyl-sn-glycero-3-phospho-1'-myo-inositol)
  • PIM5(18:1(9Z)/16:0)
126457581 1646.805608 C73H131O38P
Gangliosides LMSP0601BY05
  • NeuGcalpha2-3Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44262368 1645.965477 C79H143N3O32
Gangliosides LMSP0601CJ05
  • Galbeta1-3GalNAcbeta1-4(NeuGcalpha2-3)Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44262440 1645.965477 C79H143N3O32
Gangliosides LMSP0601FF05
  • NeuGcalpha2-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44262984 1645.965477 C79H143N3O32
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AI07
  • Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
  • type IV H(d18:1/24:1(15Z))
44260234 1644.970228 C80H144N2O32
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BM07
  • Fucalpha2-3Galbeta1-3GalNAcbeta1-4Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
44260474 1644.970228 C80H144N2O32
GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) LMSP0503AK07
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
44260570 1644.970228 C80H144N2O32
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AE07
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
  • type I B antigen(d18:1/24:1(15Z))
44260650 1644.970228 C80H144N2O32
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AE07
  • Galalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
  • type II B antigen(d18:1/24:1(15Z))
44261010 1644.970228 C80H144N2O32
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CV07
  • Gala 1-3Lex(d18:1/24:1(15Z))
  • Galalpha1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
44261554 1644.970228 C80H144N2O32

About Release Notes Help Feedback

International Collaboration

GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.

Acknowledgements

Supported by JST NBDC Grant Number JPMJND2204

Partly supported by NIH Common Fund Grant #1U01GM125267-01


Logo License Policies Site Map

Contact: support@glycosmos.org

This work is licensed under Creative Commons Attribution 4.0 International


GlyCosmos Portal v4.0.0

Last updated: August 19, 2024